LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 532 participants.
Also called NCT07202897
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 532 participants
- Sponsor
- Registry
-
NCT07202897 -
2024-511084-28-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT07202897. Randomized; no masking; primary purpose prevention. Start 2026-01-07 (actual); primary completion 2032-01-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
- Acronym
- LA-HCM
- Condition
- Hypertrophic Cardiomyopathy (HCM)
- Intervention (Drug)
- Anticoagulant treatment Rivaroxaban
- Intervention (Other)
- Best medical therapy
- Lead sponsor
- Rennes University Hospital
Record details
- Record id
cardio:ct-nct07202897- Content hash
1a9df0cc02bd3fefd59acdbc8c8d0c3781dbc3ee0fda6baea3548c224b611622